Who
Jay T. Flatley
Director
Company insider
Files Form 4 as: Director, Rivian Automotive; Director, Denali Therapeutics; Chairman and Acting CEO, Zymergen; Director, Coherent; Chief Executive Officer, Illumina; Director, Juno Therapeutics.
In numbers
- Trades disclosed
- 1,547
- Buys
- 10
- Sells
- 320
- Bought
- $4.5M
- Sold
- $531.0M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 10 Jan 2006
- Last trade
- 22 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 23 Jun 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Code A | —17,445 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Code A | —17,445 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Code A | —16,812 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,111 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,037 at $0.00 | filing |
| 18 Jun 2024filed 21 Jun 2024 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Code A | —24,224 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,967 at $0.00 | filing |
| 17 Apr 2024filed 5 Mar 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Bought | $11K1,250 at $8.84 | filing |
| 17 Apr 2024filed 5 Mar 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Bought | $11K1,250 at $8.84 | filing |
| 23 Oct 2023filed 5 Mar 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Sold | $8,366490 at $17.07 | filing |
| 23 Oct 2023filed 5 Mar 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Sold | $8,364490 at $17.07 | filing |
| 6 Jul 2023filed 5 Mar 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Bought | $10K490 at $20.67 | filing |
| 6 Jul 2023filed 5 Mar 2026 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Bought | $10K490 at $20.67 | filing |
| 21 Jun 2023filed 23 Jun 2023 | RIVN Rivian AutomotiveAutomobiles & EV | SEC FORM 4 Code A | —18,208 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,649 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Illumina To Webcast Upcoming Investor ConferenceILMN · prnewswire.com · 20 Oct 2026Rivian: Much More Than Just The R2 Story (NASDAQ:RIVN)RIVN · seekingalpha.com · 20 Oct 2026Rivian Automotive (NASDAQ:RIVN) Stock Falls 4.6% – Here's WhyRIVN · tickerreport.com · 18 Oct 2026Illumina's (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?ILMN · insidermonkey.com · 13 Oct 2026
0 headlines in the last 90 days name Jay T. Flatley; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.